XML 68 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of stock options activity
Number of
options
outstanding
Weighted-
average
exercise
price
(Per share)
Weighted-
average
remaining
contractual
term
(In years)
Aggregate
intrinsic
value
(In thousands)
Outstanding options as of December 31, 20231,722,861 $71.13 4.45$56,007 
Exercised(181,818)$23.88 
Forfeited and canceled(218,867)$92.18 
Outstanding options as of December 31, 20241,322,176 $74.15 3.05$74,838 
Options vested and exercisable as of December 31, 20241,317,265 $73.30 3.03$74,838 
Schedule of weighted average grant date fair value
Year Ended December 31,
202420232022
(In thousands, except per share amounts)
Aggregate intrinsic value of stock options exercised (1)
$8,649 $15,242 $80,839 
Total estimated grant date fair value of options vested$9,351 $28,619 $77,403 
Weighted-average grant date fair value per share of options granted$— $— $50.66 
____________________________________
(1) Aggregate intrinsic value represents the difference between the fair value of the Company’s Class A common stock as reported on the New York Stock Exchange and the exercise price of outstanding “in-the-money” options.
Schedule of restricted stock unit
Number of
awards
outstanding
Weighted-
average
grant date
fair value
(Per share)
Aggregate
intrinsic
value
(In thousands)
Unvested RSUs as of December 31, 202318,755,538 $87.56 $1,422,983 
Granted10,584,021 $61.86 
Vested(6,639,672)$92.70 
Forfeited and canceled(4,313,616)$83.09 
Unvested RSUs as of December 31, 202418,386,271 $71.96 $1,394,966 
Schedule of employee stock purchase plan
The Company used the following assumptions in the Black-Scholes option pricing model to estimate the fair value of the purchase rights issued under the 2016 ESPP:
Year Ended December 31,
Employee Stock Purchase Plan:202420232022
Fair value of common stock
$61.54 - $96.41
$47.36 - $61.55
$50.81 - $99.68
Expected term (in years)0.50
0.50
0.50
Expected volatility
38.6% - 41.8%
45.8% - 57.1%
73.2% - 97.3%
Risk-free interest rate
4.4% - 5.4%
5.3% - 5.4%
1.5% - 4.5%
Dividend rate
—%
—%
—%
Schedule of stock based compensation expense
The Company recorded stock-based compensation expense as follows:
Year Ended December 31,
202420232022
(In thousands)
Cost of revenue$22,001 $26,343 $21,136 
Research and development330,933 331,526 374,846 
Sales and marketing135,331 183,389 240,109 
General and administrative125,164 121,584 148,194 
Restructuring costs3,178 13,015 14,275 
Total$616,607 $675,857 $798,560